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2012. The aim of this study is to understand which of the validation methods recom-
mended in health economics and financial guidelines are practically used across 
different disease areas and business fields. Methods: For this study we reviewed 
guidelines, economic models for diabetes, cardiovascular diseases, and cancers, as 
well as risk-prediction models. The identified validation methods were collected 
and categorized into three groups: face validity, internal verification, and cross 
validity. Results: Twenty-two (22) economic models, 8 risk prediction models, 5 
financial and 7 health economics guidelines were identified. In the guidelines we 
found 3, 14 and 5 methods within the face validity, internal verification, and external 
validity categories respectively. Almost three quarters of the 22 methods identi-
fied were also described in the ISPOR guideline on model validation and the other 
guidelines described 5 to 15 methods. External validation was done for 14 out of the 
22 economic models reviewed in which (part of) the model results were compared 
against other clinical/epidemiology studies (14 models) or other validated models 
(10 models). Internal verification was mainly done through comparison against the 
trials that the models were built on (10 models). Out of the remaining 13 internal 
verification methods only 3 were performed for the economic models. Face valida-
tion was only performed for 3 economic models. ConClusions: This study found 
that there is a substantial gap between the validation steps recommended and those 
actually performed. Hence a more consistent and pragmatic approach needs to be 
taken to validate economic models. In addition, the validation methods performed 
need to be consistently reported.
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objeCtives: Multimorbid individuals consume a disproportionally large share 
of health care resources. Usually standard (1-component) regression techniques 
are applied to analyse costs in samples of patients with multiple chronic condi-
tions. However, the patient specific number and combination of co-occurring single 
diseases results in inhomogeneous data leading to biased estimates when using 
traditional regression techniques. In this study we analyse health care costs in a 
sample of patients suffering from multimorbidity using a more elaborate approach 
to address this heterogeneity. Methods: We used a subsample of N= 1050 patients 
from a multicentre prospective cohort study of multimorbid primary care patients 
aged 65 to 85 years in Germany who completed a questionnaire on health care utili-
zation covering a 6-month-period. We applied a finite mixture of generalized linear 
models, which belongs to the group of statistical learning algorithms, in order to 
control for unobserved heterogeneity of patient level health care costs focussing on 
the identification of multimorbidity patterns. Results: We detected four different 
groups of patients with regard to total costs. The effect of the presence of an addi-
tional disease on costs differs between these groups. Two diametrically opposed cost 
trends were detected with respect to the number of co-occurring diseases. While in 
one group containing hypertension, joint arthrosis, diabetes, gout, anxiety and lower 
limb varicosis cost increased with the number of co-occurring diseases, in a sec-
ond group including severe hearing loss, asthma/COPD, osteoporosis, neuropathies, 
Parkinson’s disease and chronic ischemic heart disease cost decreased. Diversities 
between groups were also found in the results indicated by diametrically opposed 
influence of single diseases. ConClusions: Our results indicate existing unob-
served heterogeneity in costs among patients suffering from multimorbidity with 
different combinations of single diseases which would remain unconsidered using 
standard regression techniques. Especially different costs trends were detected with 
regard to the number and nature of co-existing diseases.
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objeCtives: TSC is a multi-system genetic disorder associated with benign lesions 
throughout the body, neurological manifestations, and impaired cognition. As many 
as 8000 people in the UK may have TSC; many cases likely go undiagnosed. Long-
term morbidity and treatment burden associated with TSC are significant, suggest-
ing substantial economic burden. This preliminary study assessed presentation 
patterns of select TSC manifestations in CPRD. Methods: TSC patients were retro-
spectively identified in CPRD (Read: PK5.00) and linked Hospital Episodes Statistics 
(HES; ICD-10: Q85.1) databases. CPRD includes over 5 million active patients from UK 
primary care practices (~8% coverage). A total of 55% of practices (375) are linked to 
HES, allowing events in secondary care to be analysed (e.g. hospitalisations, proce-
dures). Patients not linked to HES were excluded. Available history was extracted for 
each patient; descriptive statistics for select TSC-related diagnoses and procedures 
are presented. All ages reported below are median values. Results: A total of 244 
patients (49% male) with a TSC diagnosis were identified; age at diagnosis was 8 
years, with 70% under 18 years. Patient data history was 20 years; 3 and 11 years 
pre/post initial TSC diagnosis. By age 4, 72% had a record of epilepsy; by 16 years, 
9% had a record of subependymal giant-cell astrocytoma (SEGA); by 18 years, 1% 
had obstructive hydrocephalus; by 43 years, 4% had renal angiomyolipoma (AML) 
[median age at initial recorded diagnosis]. ConClusions: Preliminary analyses 
affirm the utility of CPRD in a real-world study of TSC, and the many emergent TSC-
related manifestations, in a longitudinal fashion. Data are suggestive of evolving 
diagnostic and treatment patterns (30% adults) and may highlight a need for better 
coordination of adult care. Relatively low prevalence of AML was unexpected and 
sents almost 3.4% of the country’s GDP (2010). In terms of employment 23.000 are 
directly employed in the sector, while the total benefit for the Greek economy (both 
direct and indirect) is estimated to approximately 132.000 jobs. Finally, the industry 
accounts for nearly € 400 million tax revenue, half of which affects the economy 
directly. ConClusions: Taking these effects in consideration it stems that for every 
€ 1 of Value added in the production / distribution of the pharmaceutical sector some 
€ 2.6 of Value added is created as an indirect effect and € 5.3 as an induced effect. 
Additionally every job position in the sector in the pharmaceutical (production / 
distribution) sector supports 2.5 jobs due to indirect effects and almost 6 jobs in the 
economy. Finally, for every € 1 in tax revenue provided by the sector, an additional 
€ 1.6 is generated though indirect effect and a total of € 2.2 if the induced effect is 
taken into consideration.
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objeCtives: To determine through a literature review how economic evaluations 
incorporate utility data into models when estimating long-term cost-effectiveness 
of lipid lowering therapies in primary and/or secondary cardiovascular disease 
(CVD) prevention. Methods: We used MEDLINE to identify published articles 
reporting cost-effectiveness models. Inclusion criteria included: English language 
articles published from 2000-2013, studies in adults ≥ 18 years old, studies assess-
ing statins or ezetimibe for primary and/or secondary CVD prevention, and studies 
in the US, Canada, UK, Spain, Germany, Australia, Sweden, France, and Italy. Two 
researchers independently identified articles and disagreements were resolved by 
consensus. Results: Sixty-one studies fulfilled the inclusion criteria. Forty-eight 
studies assessed the long-term cost-effectiveness (≥ 10 years) of lipid-lowering ther-
apy— 20 studies were in primary CVD prevention, 19 were in secondary prevention, 
and 9 were in both primary and secondary prevention. 36/48 studies incorporated 
utility parameters into their models. 23/36 models differentiated short-term ver-
sus long-term utility impact of cardiovascular events. Eleven models were able 
to differentiate between short-term and long-term utilities through model struc-
ture, where separate health states were created for events versus post-events (e.g., 
stroke versus post-stroke), and utility values could be assigned to these health states 
accordingly. Twelve models were able to differentiate short-term versus long-term 
utilities by changing the model inputs, where different utility values were applied 
to a health state according to length of time after the event (e.g., event year versus 
subsequent years for a health state, or < 6 months versus > 6 months from time of 
event). Eleven models accounted for the occurrence of multiple events by applying 
disutilities or combining utilities multiplicatively for patients experiencing ≥ 1 event 
over time. ConClusions: Around two-thirds of the published long-term models 
differentiated short-term versus long-term utility impacts of cardiovascular events 
through model structure or utility inputs, which should be incorporated into future 
models on this topic.
PRM37
An exCel CAlCulAtoR to estiMAte RHeuMAtoid ARtHRitis Costs in 
tuRkey
Baser O.1, Burkan A.2, Baser E.3, Koselerli R.2, Ertugay E.2, Altinbas A.4
1STATinMED Research/The University of Michigan, Ann Arbor, Michigan, MI, USA, 2Social 
Security Institution, Ankara, Turkey, 3STATinMED Research, Ankara, Turkey, 4Diskapi Yildirim 
Beyazi Education and Research Hospital, Gastroenterology Clinic, and STATinMED Research, 
Ankara, Turkey
objeCtives: To build an Excel calculator, taking demographic and clinical charac-
teristics of rheumatoid arthritis (RA) patients in Turkey, and estimate the annual 
health care costs. Methods: 2009-2011 data from MEDULA, the Turkish national 
health insurance database, was used for the study. RA patients (ages 18-99) were 
identified for the identification period (June 1, 2010 - December 31, 2010) using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes. Patients were grouped as prevalent and incident cases and required 
to have two RA diagnoses at least 60 days apart. In order to estimate risk-adjusted 
total annual costs for prevalent and incident cases, generalized linear models 
(GLMs) were used. Patients’ demographic and clinical characteristics were factors 
to determine the expected annual cost value, with coefficients of the charac-
teristics built in the Excel calculator. A marginal effects table was created after 
GLM estimation by using such calculation. Results: A total of 2,613 patients 
met all inclusion criteria, of which 693 were incident and 1,920 prevalent cases. 
Patients’ demographic and clinical characteristics were entered into the Excel 
calculator. Risk-adjusted annual total costs were calculated at € 2,021 for prevalent 
cases and € 1,818 for incident cases. The most expensive contributor to annual 
expenditures was prior biologic use for both groups. Prevalent patients who were 
prescribed disease-modifying anti-rheumatic drugs (DMARDs) in the baseline 
period incurred € 5,898 more costs than those who were not. For incident cases, 
male patients incurred lower costs (€ 1,818 - € 708 = € 1,110), whereas respiratory 
comorbid conditions increased the total expected health care cost of incident RA 
patients by € 916 (€ 1,818 + € 916 = € 2,734). ConClusions: In outcomes research, an 
Excel calculator serves as an important tool to estimate and compare RA-related 
health care costs.
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objeCtives: Health technology agencies and payers rely on economic models to 
evaluate the value of new treatments. It is therefore critical to ensure the scientific 
credibility of these models through validation, which is also required by NICE since 
